Ginkgo Bioworks Holdings, Inc. DNA NYSE

Ginkgo Bioworks Holdings, Inc. (DNA) reported total assets of $1.12B and total liabilities of $611.11M for fiscal year 2025, resulting in total equity of $508.59M.

The company held $422.62M in cash and short-term investments. Total debt stood at $417.08M, with net debt of $249.88M. The Debt-to-Equity (D/E) ratio was 0.82 (moderate).

Current ratio is 4.92, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (75/100, Pass) — Debt-to-Equity of 0.82, current ratio of 4.92 — balance sheet is strong
• MOAT (58/100) — Total assets $1.12B and equity $508.59M support the company's competitive scale
• VALUE (79/100) — Debt-to-Equity 0.82 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 45/100 with 2/7 criteria passed.

VIR

Vir Biotechnology, Inc.

$10.05

+7.95%

AVBP

ArriVent BioPharma, Inc. Common Stock

$27.64

+3.17%

IOVA

Iovance Biotherapeutics, Inc.

$3.64

+5.20%

MBX

MBX Biosciences, Inc. Common Stock

$32.81

-0.03%

MGTX

MeiraGTx Holdings plc

$11.29

+17.24%

MRVI

Maravai LifeSciences Holdings, Inc.

$3.28

+7.19%

ATXS

Astria Therapeutics, Inc.

$12.58

+0.00%

ARVN

Arvinas, Inc.

$11.00

+3.97%